GRAIL (NASDAQ:GRAL) Insider Andrew John Partridge Sells 1,491 Shares

GRAIL, Inc. (NASDAQ:GRAL) insider Andrew John Partridge sold 1,491 shares of GRAIL stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $61.08, for a total transaction of $91,070.28. Following the transaction, the insider owned 163,738 shares in the company, valued at approximately $10,001,117.04. This trade represents a 0.90% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

GRAIL Stock Performance

GRAL opened at $59.98 on Friday. GRAIL, Inc. has a fifty-two week low of $29.95 and a fifty-two week high of $118.84. The firm’s fifty day moving average is $57.27 and its 200 day moving average is $75.49. The stock has a market cap of $2.57 billion, a price-to-earnings ratio of -5.78 and a beta of 3.15.

GRAIL (NASDAQ:GRAL) last released its earnings results on Tuesday, May 5th. The company reported ($2.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.76) by $0.47. GRAIL had a negative net margin of 253.22% and a negative return on equity of 16.42%. The company had revenue of $40.79 million for the quarter, compared to analysts’ expectations of $39.16 million. On average, equities research analysts predict that GRAIL, Inc. will post -10.99 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on GRAL. Robert W. Baird set a $70.00 target price on shares of GRAIL in a research note on Wednesday, May 6th. TD Cowen lifted their target price on shares of GRAIL from $65.00 to $69.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. The Goldman Sachs Group began coverage on shares of GRAIL in a research note on Friday. They set a “neutral” rating and a $60.00 target price on the stock. Wall Street Zen upgraded shares of GRAIL from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, Piper Sandler lifted their target price on shares of GRAIL from $54.00 to $56.00 and gave the company a “neutral” rating in a research note on Wednesday, May 6th. Four investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $67.00.

Institutional Trading of GRAIL

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE increased its holdings in GRAIL by 29.0% in the 1st quarter. Bank of America Corp DE now owns 914,114 shares of the company’s stock valued at $47,241,000 after acquiring an additional 205,611 shares during the last quarter. California State Teachers Retirement System increased its holdings in GRAIL by 27.9% in the 1st quarter. California State Teachers Retirement System now owns 44,470 shares of the company’s stock valued at $2,298,000 after acquiring an additional 9,696 shares during the last quarter. Empowered Funds LLC bought a new stake in GRAIL in the 1st quarter valued at $311,000. Gamco Investors INC. ET AL increased its holdings in GRAIL by 170.7% in the 1st quarter. Gamco Investors INC. ET AL now owns 66,758 shares of the company’s stock valued at $3,450,000 after acquiring an additional 42,100 shares during the last quarter. Finally, Sei Investments Co. increased its holdings in GRAIL by 53.0% in the 1st quarter. Sei Investments Co. now owns 12,092 shares of the company’s stock valued at $625,000 after acquiring an additional 4,191 shares during the last quarter.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.